Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2014
10/02/2014WO2014159745A1 Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
10/02/2014WO2014159733A1 Compounds for treatment of fibrosis diseases
10/02/2014WO2014159720A1 Methods and compositions for inhibiting glyoxalase 1 (glo1)
10/02/2014WO2014159703A2 N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus
10/02/2014WO2014159690A1 Dna-pk inhibitors
10/02/2014WO2014159688A1 Bioactive concentrates and uses thereof
10/02/2014WO2014159684A1 Compositions and methods for treating or preventing insulin resistance or abnormal levels of circulating lipids in a mammal
10/02/2014WO2014159679A1 Methods for using lubiprostone to absorb fluid from the subretinal space
10/02/2014WO2014159657A1 Pyridinyl and pyrimidinyl sulfonamide derivatives as chemokine receptor modulators
10/02/2014WO2014159637A1 Methods of treating b2-bradykinin receptor mediated angioedema
10/02/2014WO2014159592A2 Modified hyaluronan and uses thereof in cancer treatment
10/02/2014WO2014159591A1 Substituted 7-azabicycles and their use as orexin receptor modulators
10/02/2014WO2014159582A1 Amphetamine transdermal compositions with acrylic block copolymer
10/02/2014WO2014159576A1 Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
10/02/2014WO2014159573A1 Methylphenidate transdermal compositions with rubber-based adhesives
10/02/2014WO2014159559A1 Fused furans for the treatment of hepatitis c
10/02/2014WO2014159511A1 Deuterated pacritinib
10/02/2014WO2014159500A1 Regulation of cancer using natural compounds and/or diet
10/02/2014WO2014159392A1 Bromodomain binding reagents and uses thereof
10/02/2014WO2014159377A1 Compositions containing tanaproget and natural estrogens
10/02/2014WO2014159371A1 Drink product and use thereof
10/02/2014WO2014159353A1 Solid state forms of vemurafenib hydrochloride
10/02/2014WO2014159343A1 Method of stimulating immune cell migration
10/02/2014WO2014159340A1 Benzonatate modified release solid tablets and capsules
10/02/2014WO2014159275A1 Controlled-release pharmaceutical compositions comprising lamotrigine and methods of producing same
10/02/2014WO2014159251A2 Inhibiting neurotransmitter reuptake
10/02/2014WO2014159248A1 Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
10/02/2014WO2014159245A1 Opioid receptor modulator dosage formulations
10/02/2014WO2014159224A1 Histone deacetylase inhibitors and compositions and methods of use thereof
10/02/2014WO2014159218A1 Histone deacetylase inhibitors and compositions
10/02/2014WO2014159214A1 Histone deacetylase inhibitors and compositions and methods of use thereof
10/02/2014WO2014159210A1 Histone deacetylase inhibitors and compositions and methods of use thereof
10/02/2014WO2014159171A1 Methods of treating lung cancer
10/02/2014WO2014159151A1 Methods for preparing sglt2 inhibitors
10/02/2014WO2014159087A1 Radiolabeled anti-glypican-3 immunoconjugates for immuno-pet imaging of hepatocellular carcinoma
10/02/2014WO2014159080A1 Methods for determining active ingredients of an herbal medicine, sources of and catalytic pathways for production thereof
10/02/2014WO2014159076A1 Inhibitors of human immunodeficiency virus replication
10/02/2014WO2014159067A1 Thienylindole azepines as serotonin 5-ht2c receptor ligands and uses thereof
10/02/2014WO2014159054A1 Gpr120 agonists for the treatment of type ii diabetes
10/02/2014WO2014159012A1 Azetidinyloxyphenylpyrrolidine compounds
10/02/2014WO2014158998A1 Substituted pyridine and pyrazine compounds as pde4 inhibitors
10/02/2014WO2014158952A1 Hydrochloride salts of an antibiotic compound
10/02/2014WO2014158943A1 Tyrosinase inhibitors
10/02/2014WO2014158942A1 Compositions for improving the appearance of skin
10/02/2014WO2014158916A1 Substituted naphthyridine and quinoline compounds as mao inhibitors
10/02/2014WO2014158875A1 Novel therapy for prostate carcinoma
10/02/2014WO2014158795A1 Diagnosis and treatment of fibrosis
10/02/2014WO2014158761A1 Aromatic carboxylic acids in combination with aromatic hydroxyamides for inactivating non-enveloped viruses
10/02/2014WO2014158654A1 Ship1 modulators and methods related thereto
10/02/2014WO2014158640A1 Improved process for the preparation of certain triaryl rhamnose carbamates
10/02/2014WO2014158554A1 Process for making hmf from sugars with reduced byproduct formation, and improved stability hmf compositions
10/02/2014WO2014158547A1 Compositions for improving cell viability and methods of use thereof
10/02/2014WO2014158528A1 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
10/02/2014WO2014158467A1 Combination
10/02/2014WO2014158356A1 Nutritional supplement targeting meibomian glands
10/02/2014WO2014158321A1 Resorption enhancers as additives to improve the oral formulation of low molecular weight heparins
10/02/2014WO2014158302A1 Novel sphingosine 1-phosphate receptor antagonists
10/02/2014WO2014158256A1 Omega-3 pentaenoic acid compositions and methods of use
10/02/2014WO2014158242A1 Method for the treatment of fatty liver disease
10/02/2014WO2014158165A1 Composition and method for inducing epo-mediated haemoglobin expression and mitochondrial biogenesis in nonhaematopoietic cell
10/02/2014WO2014158119A1 Aqueous solution composition containing ipratropium and oxymetazoline
10/02/2014WO2014158118A1 Suspension composition containing ipratropium and oxymetazoline
10/02/2014WO2014158045A1 Dimeric quaternary pyridinium salts possessing biocidal activity
10/02/2014WO2014158033A1 Stabilized vitamin d formulations
10/02/2014WO2014157994A1 Novel oxazolidinone derivative as cetp inhibitor, its preparation method, and pharmaceutical composition comprising the same
10/02/2014WO2014157989A1 Stabilized composition containing voriconazole
10/02/2014WO2014157966A1 Pharmaceutical composition for preventing or treating ovary granulosa cell tumors containing glycogen synthase kinase-3 beta inhibitor as active ingredient, and functional health food composition
10/02/2014WO2014157918A1 Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells
10/02/2014WO2014157860A1 Process for the preparation of high purity olanzapine and crystalline form ii thereof
10/02/2014WO2014157852A1 Sustained-release medicinal composition containing eperisone as active ingredient
10/02/2014WO2014157851A1 Eperisone pharmaceutical composition having improved preservability and ph stability
10/02/2014WO2014157740A1 Pyrazole derivative
10/02/2014WO2014157727A1 Therapeutic agent for eye disorder
10/02/2014WO2014157687A1 1,2,4-triazine-6-carboxamide derivative with acetamide group
10/02/2014WO2014157672A1 Substituted biaryl compound
10/02/2014WO2014157653A1 Processes for preparing optically active diamine derivatives
10/02/2014WO2014157635A1 Sulfamoylbenzene derivative and drug application
10/02/2014WO2014157623A1 Therapeutic agent for pulmonary hypertension, which contains benzophenone derivative or salt thereof
10/02/2014WO2014157622A1 Antiviral agent against non-enveloped viruses and use thereof
10/02/2014WO2014157612A1 Method for producing (1s,4s,5s)-4-bromo-6- oxabicyclo[3.2.1]octane-7-one
10/02/2014WO2014157607A1 Method for improving optical purity of 2-hydroxycarboxylic acid or derivative thereof
10/02/2014WO2014157603A1 Pharmaceutical composition for oral administration
10/02/2014WO2014157600A1 Condensed heterocyclic compound or salts thereof, agricultural and horticultural pesticide containing said compound, and method for using same
10/02/2014WO2014157569A1 Heterocyclic compound
10/02/2014WO2014157540A1 Anti-inflammatory agent
10/02/2014WO2014157444A1 Low-dose antitumor agent including irinotecan hydrochloride hydrate
10/02/2014WO2014157443A1 Antitumor agent including irinotecan hydrochloride hydrate
10/02/2014WO2014157437A1 Propellane derivative
10/02/2014WO2014157436A1 Pharmaceutical composition for external application
10/02/2014WO2014157382A1 Sphingosine kinase inhibitor
10/02/2014WO2014157380A1 Therapeutic agent for wounds or fibrosis
10/02/2014WO2014157158A1 Phenyl derivative
10/02/2014WO2014157137A1 Oral administration preparation with masked bitterness of silodosin
10/02/2014WO2014157047A1 Therapeutic agent for neurodegenerative diseases
10/02/2014WO2014156505A1 Jelly-like tablet and jelly-like lozenge using same
10/02/2014WO2014156462A1 Agent for inducing differentiation of white adipocytes into brown-like adipocytes
10/02/2014WO2014156196A1 Therapeutic agent for type 2 diabetes
10/02/2014WO2014155397A1 Oral suspension for treating eosinophilic esophagitis
10/02/2014WO2014155387A1 Extended release dosage forms of quetiapine salts
10/02/2014WO2014155376A1 Methods of treating myeloid leukemia
1 ... 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 ... 7860